Menu ×

HEALTHCARE & PHARMACEUTICAL

Immunotherapy Drugs Market Segmentation by Type [Targeted Immunotherapies (Monoclonal Antibodies, Checkpoint Inhibitors, and Therapeutic Cancer Vaccines), Adoptive Cell Therapies {Tumor-Infiltrating Lymphocyte (TIL) Therapy and Natural Killer (NK) Cell Therapy}, Oncolytic Virus Therapy, Immune System Modulators {Interleukins, Interferons, and Immunomodulators (IMiDs)}, and Others]; by Therapy Area (Cancer, Infectious Diseases and Others) – Global Demand Analysis & Opportunity Outlook 2029

  • Report ID: 60
  • Text Size:

Extensive insights into the Growth of Immunotherapy Drugs Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

IN THE NEWS

  • June 29, 2020: The United States Food and Drug Administration announced the approval of Keytruda (pembrolizumab), an immunotherapy (anti-PD-1 therapy) drug developed by Merck & Co., Inc., for the first-line treatment of mismatch repair deficient (dMMR) or unresectable or metastatic microsatellite instability-high (MSI-H) colorectal cancer.

Global Immunotherapy Drugs Market Growth Highlights 2020-2029

The global immunotherapy drugs market is envisioned to exhibit a significant CAGR during the forecast period, i.e., 2021-2029. Increasing prevalence of targeted diseases worldwide, along with the increasing adoption of immunotherapy drugs over conventional treatments, and the rising demand for oncology biosimilars, and monoclonal antibodies are some of the major factors anticipated to drive the market growth. Further, growing advancements in cancer research and immunotherapy treatment, such as cellular immunotherapy, melanoma immunotherapy, immunotherapy drugs for lung cancer, and others, and the increasing cancer immunotherapy drugs approved by the United States Food and Drug Administration (FDA) are further anticipated to drive the growth of the global immunotherapy drugs market in the coming years.

Introduction to Immunotherapy Drugs

Immunotherapy is referred to the treatment of disease by suppressing or activating the immune system of the human body. Also known as biological therapy, the subject has become of great interest amongst the pharmaceutical companies, clinicians, and researchers in the recent years owing to the increasing success rate of the therapy to treat different types of cancer diseases. Immunotherapy restores or improves immunity system to restrict growth of cancer cells, preventing it to spread to other parts of the body and also enables the immunity system to destroy the cancer cells from the body.

Market Size and Forecast

The global immunotherapy drugs market is thriving on account of the growing need for the cure and treatment of chronic and targeted diseases globally, along with the increasing favorable initiatives of the government of nations to enhance research and development in the field of various targeted diseases, and the growing investments of the pharmaceutical companies for the development of advanced oncology biosimilars and other immunotherapy drugs. For instance, on the 12th of January, 2016, the then President of the United States, Barack Obama, tasked the then Vice President, Joe Biden, to lead a research initiative called the “Cancer Moonshot” which aimed to deploy a large team of oncologists, researchers and other healthcare workers to progress toward a cure for cancer prevention, diagnosis, and treatment, and further to help end cancer. Until 2020, the National Cancer Institute (NCI) of the National Institute of Health (NIH), U.S. Department of Health and Human Sciences, invested over USD 1 billion in funding to support more than 240 research projects across around 70 cancer science initiatives. The initiatives that had been established to address the goals of the project is mentioned below:

cancer Moonshot Research Initiatives

Few of the initiatives that supported on expanding the benefits of immunotherapy included the development of Immuno-Oncology Translational Network (IOTN) for adults, Pancreatic Cancer Microenvironment Network (PaCMEN) for finding immunotherapies for pancreatic tumor, and the development of Pediatric Immunotherapy Discovery and Development Network (PI-DDN) among others.

The global immunotherapy drugs market is segmented by therapy area into cancer, infectious diseases, inflammatory & autoimmune diseases, and others. Among these segments, the cancer segment is anticipated to register the largest market share by the end of 2021. The growth of the segment can be attributed to the growing prevalence of cancer diseases globally, and the increasing need for prevention and cure of such chronic diseases, backed by the rising burden and the risks associated with the disease. According to the statistics by the World Health Organization (WHO), in the year 2018, around 9.6 million deaths was caused due to cancer, a disease which is also the second leading cause of death around the world. Moreover, increasing research and advancements in immune-oncology, along with the growing research for immunotherapy cure for stage-4 cancer, are some of the additional factors anticipated to drive the growth of the segment during the forecast period. CLICK TO DOWNLOAD SAMPLE REPORT

Immunotherapy Drugs Market Share Segmentation by Therapy Area

Growth Drivers

Growing Adoption of Targeted Therapies for Treating Cancer

Targeted therapy is referred to the process of treating cancer by using drugs to target specific proteins and genes that are involved in the growth and survival of the cancer cells. The therapy is either used individually or with chemotherapy and other treatments. Over the past few years, with increasing research and advancements in drugs developed for prevention and cure of cancer diseases, the U.S. FDA has approved several targeted therapies for treating different forms of cancer. There are several types of targeted therapy that include angiogenesis inhibitors, immunotherapies, and apoptosis inducers among others, out of which, the most common ones are monoclonal antibodies type of immunotherapy and small-molecule drugs, such as angiogenesis inhibitors. Backed by the growing prevalence of cancer diseases globally, and the advancements in research, healthcare practitioners are increasingly adopting targeted therapies for treating cancer, which is anticipated to drive the market growth in the coming years.

Restraints

High Cost Associated with Immunotherapy Treatment

The treatment of cancer using immunotherapy drugs is significantly high and is not affordable by several low- and middle-income groups. Moreover, lack of proper healthcare infrastructure in several nations around the globe is also anticipated to hamper the adoption of immunotherapy drugs, and in turn lower the market growth during the forecast period.

Market Segmentation

Our in-depth analysis of the global immunotherapy drugs market includes the following segments:

By Type

  • Targeted Immunotherapies
    • Monoclonal Antibodies
      • Naked Monoclonal Antibodies
      • Conjugated Monoclonal Antibodies
      • Bispecific Monoclonal Antibodies
    • Checkpoint Inhibitors or Tumor-Agnostic Treatments
      • PD-1
        • Pembrolizumab (Keytruda)
        • Nivolumab (Opdivo)
        • Cemiplimab (Libtayo)
      • PD-L1
        • Atezolizumab (Tecentriq)
        • Durvalumab (Imfinzi)
        • Avelumab (Bavencio)
      • CTLA-4 Inhibitor
        • Ipilimumab (Yervoy)
    • Therapeutic Cancer Vaccines
      • Preventive
        • Cervarix, Gardasil, and Gardasil-9
        • Hepatitis B (HBV) Vaccine (HEPLISAV-B)
      • Treatment
        • Sipuleucel-T (Provenge)
        • Talimogene Laherparepvec (T-VEC) (Imlygic)
        • Bacillus Calmette-Guerin (BCG)
  • Adoptive Cell Therapies
    • Tumor-Infiltrating Lymphocyte (TIL) Therapy
    • Engineered T-Cell Receptor (TCR) Therapy
    • CAR T-Cell Therapy
    • Natural Killer (NK) Cell Therapy
  • Oncolytic Virus Therapy
  • Immune System Modulators
    • Interleukins
    • Interferons
    • Immunomodulators (IMiDs)
      • Imiquimod (Aldara, Zyclara)
      • Lenalidomide (Revlimid)
      • Pomalidomide (Pomalyst)
      • Thalidomide (Thalomid, and Contergan)
      • Bacillus Calmette-Guerin or BCG
  • Others

By Therapy Area

  • Cancer
  • Infectious Diseases
  • Inflammatory & Autoimmune Diseases
  • Others

By Region

On the basis of regional analysis, the global immunotherapy drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa regions. The market for immunotherapy drugs in North America is estimated to register the largest market share by the end of 2029 on the back of presence of several key players in nations, such as the United States, along with the growing number of new cancer cases registered every year in the nations in the region. According to the statistics by the Centers for Disease Control and Prevention (CDC), the total number of new cancers registered annually in the United States grew from 1,291.6 thousand cases in the year 1999 to 1,701.3 thousand cases in the year 2017.

Annual Number of New Cancers (in thousand cases), United States

The global immunotherapy drugs market is further classified on the basis of region as follows:

  • North America (US, Mexico and Canada) Market size, Y-O-Y growth and Opportunity analysis.
  • Europe (Germany, France, Italy, Belgium, Spain, UK, Russia, Netherlands and Other parts of Europe) Market size, Y-O-Y growth and Opportunity analysis.
  • Asia Pacific (Japan, India, China, Malaysia, Australia, Indonesia, Thailand and rest of Asia Pacific) Market size, Y-O-Y growth and Opportunity analysis.
  • Latin America (Argentina, Brazil and rest of Latin America) Market size, Y-O-Y growth and Opportunity analysis.
  • Middle East & Africa (Saudi Arabia, Egypt, United Arab Emirates and South Africa) Market size, Y-O-Y growth and Opportunity analysis.

Top Players Dominating the Market

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2020 Research Nester. All Rights Reserved